

Cough Syrup Gets Recalled While COVID Shots Get a Free Pass



[The Telegraph](#) recently reported that the public has been told to stop taking cough and cold medicines over safety fears concerning the drug pholcodine, an opioid cough suppressant.

Twenty of the common cough and cold medicines, including Day and Night Nurse capsules, have been urgently withdrawn from the market on the order of the drug regulators because of concerns about a “very rare” risk of anaphylaxis, a life-threatening adverse event.

When it comes to the mRNA COVID-19 vaccines, the regulatory double standards have never been so glaringly obvious.

Anaphylaxis was identified as an important risk by the European Medicines Agency, as early as December 2020, in the EMA’s CHMP (Committee for Medicinal Products for Human Use) [assessment report](#) on the Pfizer-BioNTech COVID-19 vaccine, seen below.

Signal determined to be Important identified risk							
Anaphylaxis	08 Dec 2020	Closed	30 Dec 2020	Post-authorization reports of anaphylaxis; EMA request to include as an Important identified	Post-authorization reports of anaphylaxis	Review of unblinded clinical study data; review of post-authorization data	Anaphylaxis was included in the EU-RMP and US-PVP as an Important Identified Risk and was included as an adverse reaction in

				risk in EU-RMP and as an adverse reaction in EU SmPC at time of conditional approval; FDA request to include it as an Important Identified Risk in the US PVP			the Section 4.8 of the CDS and EU SmPC.
--	--	--	--	---	--	--	---

Also, in the EU's first Periodic Safety Update [Report](#), which I have previously [analysed](#), anaphylaxis was again flagged as an important identified risk.

COVID-19 mRNA vaccine (nucleoside modified)
Periodic Safety Update Report (PSUR) I

Reporting Period
19 December 2020 through 18 June 2021

16.3.1. Evaluation of Important Identified Risks

Evaluation of incremental data for the important identified risk Anaphylaxis is provided below.

Table 20. Evaluation of Important Identified Risks

Important Identified Risk: Anaphylaxis

Search criteria^a: Anaphylactic reaction, Anaphylactic shock, Anaphylactoid reaction, Anaphylactoid shock

In this pharmacovigilance report, 3,827 relevant cases (individuals) were identified from the post-authorization data. The country with the highest incidence was Japan, followed by the US and the UK.

The highest number of cases reported were among women, a shocking 3,182 cases compared to 454 cases for men, with a median age of 44. The fact that 7 times more cases were reported for women is nothing new. Back in December 2021, I [analysed](#) the Pfizer-prepared [document](#) for the FDA, covering the 3-month period, Dec 2020 through Feb 28, 2021 – in the case of anaphylaxis- women were 8 times more affected.

So, 98 percent of the relevant adverse events (including anaphylactic reaction, anaphylactic shock, anaphylactoid reaction and anaphylactoid shock) were classified as serious!

Furthermore, for 92 percent of the events, the time elapsed for an adverse event to occur after vaccine administration was less than 24 hours.

- Number of relevant events: 3919.
- Relevant event seriousness: serious (3873), non-serious (46).
- Reported relevant PTs: Anaphylactic reaction (3418), Anaphylactic shock (421), Anaphylactoid reaction (75), Anaphylactoid shock (5).⁵¹
- Time to event onset (n = 3288), range:<24 hours to 180 days, median 0 days.
 - <24 hours: 3030 events;
 - 1 day: 138 events;
 - 2-7 days: 84 events;
 - 8-14 days: 20 events;
 - 15-30 days: 9 events;
 - 31-181 days: 6 events.

Fatal outcomes

Of the 3,922 events, 28 were fatal, and for a staggering 704, the outcome was unknown. No case numbers were given for fatal outcomes.

- Relevant event outcome: fatal (28), resolved/resolving (2,961), resolved with sequelae (56), not resolved (173), unknown (704).

Cases by age group

Of the 3,827 relevant cases (individuals), 23 were from the pediatric age group and 3,021 were from the adult age group.

Presence of comorbidities

What's noteworthy is that roughly 2/3 of all anaphylaxis cases did **not** have any comorbidities (underlying health issues).

Risk Assessment of New Information:

Based on the interval data, no new safety information was identified pertaining to the risk of anaphylaxis with BNT162b2.

This risk is communicated in the BNT162b2 CDS, Section 4.4, General recommendations, which includes information on appropriate action to be taken, as follows: "As with all injectable vaccines, appropriate medical treatment and supervision must always be readily available in case of a rare anaphylactic event following the administration of the vaccine. The administration of TRADENAME should be postponed in individuals suffering from acute severe febrile illness." This risk is also listed in the CDS Section 4.8, Undesirable effects, Appendix A, Appendix B.

This risk will continue to be monitored through routine pharmacovigilance.

Given what has transpired since the mRNA COVID-19 vaccines have been rolled out, it comes as no surprise to read: **"no new safety information was identified** pertaining to the risk of anaphylaxis with BNT162b2" (Pfizer-BioNTech COVID-19 vaccine). The reason given (or the excuse they hide behind) is that 'this risk is communicated . . . which includes information on appropriate action to be taken, as follows: "As with all injectable vaccines, appropriate medical treatment and supervision must always be readily available in case of a rare anaphylactic event following the administration of the vaccine."

Under [Regulation 174](#), *Information for UK healthcare Professionals*, which was last revised in Dec 2021, the following is stated:

4.4 Special warnings and precautions for use

Hypersensitivity and anaphylaxis

Events of anaphylaxis have been reported. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following the administration of the vaccine.

Close observation for at least 15 minutes is recommended following vaccination. A second dose of the vaccine should not be given to those who have experienced anaphylaxis to the first dose of the COVID-19 mRNA Vaccine BNT162b2.

What's more, Pfizer/BioNTech's lipid nanoparticle ingredients ALC-0159 and ALC-0315 have never been included in any licensed drug before. ALC-0159 contains PEG (Polyethylene glycol),

which is [known to cause anaphylaxis](#).

It's unequivocal: anaphylaxis was a known life-threatening adverse event around the same time emergency use authorization was granted for the Pfizer-BioNTech COVID-19 vaccine. Yet, because it's an "injectable vaccine," it somehow has gotten a free pass from all the drug regulators, no matter how much damning data accumulates when a cough syrup or capsule, on the other hand, gets urgently recalled on the basis of "a very rare risk of anaphylaxis."

Republished from [Brownstone Institute](#).